A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Vivoryon Therapeutics N.V.
- Target Recruit Count
- 259
- Registration Number
- NCT04498650
- Locations
- 🇩🇪
Institut für Studien zur Psychischen Gesundheit (ISPG), Mannheim, Germany
🇪🇸Unidad de Neurociencias. Hospital Victoria Eugenia, Seville, Spain
🇩🇪Universitätsklinikum Schleswig-Holstein (UKSH), Klinik für Neurologie, Kiel, Germany
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Vivoryon Therapeutics N.V.
- Target Recruit Count
- 112
- Registration Number
- NCT03919162
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸The Neuron Clinic, Chula Vista, California, United States
Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- Vivoryon Therapeutics N.V.
- Target Recruit Count
- 120
- Registration Number
- NCT02389413
- Locations
- 🇪🇸
Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Spain
🇳🇱Alzheimer Research Center, Amsterdam, Netherlands
🇪🇸Hospital de la Santa Creu i Sant Pau, Neurology Department, Memory Unit, Barcelona, Spain
Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Vivoryon Therapeutics N.V.
- Target Recruit Count
- 18
- Registration Number
- NCT02190708
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath